Elevated 80K-H protein in breast cancer: A role for FGF-1 stimulation of 80K-H

International Journal of Biological Markers

Volumn 18, Issue 2, 2003, Pages 89-98

  Forough, Reza ^a   Lindner, L ^a   Partridge, C ^a   Jones, B ^a   Guy, G ^b   Clark, G ^c  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

80K H; Angiogenesis; Breast cancer; FGF 1 receptor; Infiltrating ductal carcinoma; Invasive ductal carcinoma; Marker; Nuclear localization

Indexed keywords

ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PROGESTERONE RECEPTOR; PROTEIN KINASE C; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR; GLUCOSIDASE; MARCKS PROTEIN; MEMBRANE PROTEIN; MYRISTOYLATED ALANINE-RICH C KINASE SUBSTRATE; PHOSPHOPROTEIN; PRKCSH PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; RECOMBINANT PROTEIN; SIGNAL PEPTIDE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST EPITHELIUM; CANCER GRADING; CELL CULTURE; CELL FRACTIONATION; CELL GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; COMPUTER ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROVASCULATURE; MOLECULAR MECHANICS; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; ACTIVE TRANSPORT; BREAST TUMOR; CELL DIVISION; CHEMISTRY; FEMALE; GENETICS; METABOLISM; PATHOLOGY;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS;

ACTIVE TRANSPORT, CELL NUCLEUS; BREAST NEOPLASMS; CELL DIVISION; FEMALE; FIBROBLAST GROWTH FACTOR 1; GLUCOSIDASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; PHOSPHOPROTEINS; PROTEIN TRANSPORT; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0042200210     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.563     Document Type: Article

References (44)

1. Osteen RT. Breast Cancer. In: The American Cancer Society's Clinical Oncology. Atlanta, GA: The American Cancer Society, Inc., 2001; 251.
2. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast cancer patients. Int J Cancer 2000; 89: 484-7.
3. Suga K, Imai K, Eguchi H, Hayashi Si S, Higashi Y, Nakachi K. Molecular significance of excess body weight in postmenopausal breast cancer patients, in relation to expression of insulin-like growth factor I receptor and insulin-like growth factor II genes. Jpn J Cancer Res 2001; 92: 127-34.
4. Pilichowska M, Kimura N, Fujiwara H, Nagura H. Immunohistochemical study of TGF-alpha, TGF-beta1, EGFR, and IGF-1 expression in human breast carcinoma. Mod Pathol 1997; 10: 969-75.
5. Castellani R, Visscher DW, Wykes S, Sarkar FH, Crissman JD. Interaction of transforming growth factor-alpha and epidermal growth factor receptor in breast carcinoma. An immunohistologic study. Cancer 1994; 73: 344-9.
6. Shao ZM, Nguyen M, Barsky SH. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 2000; 19: 4337-45.
7. Bhardwaj B, Klassen J, Cossette N, et al. Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. Clin Cancer Res 1996; 2: 773-82.
8. Jacquemier J, Adelaide J, Parc P, et al. Expression of the FGFR1 gene in human breast carcinoma cells. Int J Cancer 1994; 59: 373-8.
9. Zammit C, Barnard R, Gomm J, et al. Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer. J Pathol 2001; 194: 27-34.
10. La Rosa S, Sessa F, Colombo L, Tibiletti MG, Furlan D, Capella C. Expression of acidic fibroblast growth factor (aFGF) and fibroblast growth factor receptor 4 (FGFR4) in breast fibroadenomas. J Clin Pathol 2001; 54: 37-41.
11. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989; 58: 575-606.
12. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001; 2: reviews 3005.1-3005.12 (www.genomebiology.com).
13. Adnane J, Gaudray P, Dionne CA, et al. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 1991; 6: 659-63.
14. Schmitt JF, Susil BJ, Hearn MT. Aberrant FGF-2, FGF-3, FGF-4 and C-erb-B2 gene copy number in human ovarian, breast and endometrial tumours. Growth Factors 1996; 13: 19-35.
15. Zhang L, Kharbanda S, Chen D, et al. MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice. Oncogene 1997; 15: 2093-108.
16. Zhang L, Kharbanda S, Hanfelt J, Kern FG. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells. Cancer Res 1998; 58: 352-61.
17. McLeskey SW, Zhang L, Kharbanda S, et al. Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res Treat 1996; 39: 103-17.
18. Kanai M, Goke M, Tsunekawa S, Podolsky DK. Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein. J Biol Chem 1997; 272: 6621-8.
19. Kligman D, Patel J. A protein modulator stimulates C kinase-dependent phosphorylation of a 90K substrate in synaptic membranes. J Neurochem 1986; 47: 298-303.
20. Patel J, Kligman D. Purification and characterization of an Mr 87,000 protein kinase C substrate from rat brain. J Biol Chem 1987; 262: 16686-91.
21. Hirai M, Shimizu N. Purification of two distinct proteins of approximate Mr 80,000 from human epithelial cells and identification as proper substrates for protein kinase C. Biochem J 1990; 270: 583-9.
22. Sakai K, Hirai M, Minoshima S, Kudoh J, Fukuyama R, Shimizu N. Isolation of cDNAs encoding a substrate for protein kinase C: nucleotide sequence and chromosomal mapping of the gene for a human 80K protein. Genomics 1989; 5: 309-15.
23. Thornalley PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-grand) 1998; 44: 1013-23.
24. Li YM, Mitsuhashi T, Wojciechowicz D, et al. Molecular identity and cellular distribution of advanced glycation end-product receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 1996; 93: 11047-52.
25. Goh KC, Lim YP, Ong SH, et al. Identification of p90, a prominent tyrosine-phosphorylated protein in fibroblast growth factor-stimulated cells, as 80K-H. J Biol Chem 1996; 271: 5832-8.
26. Allred DC, Clark GM, Tandon AK, McGuire WL. Immunohistochemistry on histological sections from small (50 mg) samples of pulverized breast cancer. J Histotechnol 1993; 16: 117-20.
27. Nikkari ST, Geary RL, Hatsukami T, et al. Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinases-1 in restenosis after carotid end-arterectomy. Am J Pathol 1996; 148: 777-83.
28. Ong SH, Goh KC, Lim YP, et al. Suc1-associated neurotrophic factor target (SNT) protein is a major FGF-stimulated tyrosine phosphorylated 90-kDa protein which binds to the SH2 domain of GRB2. Biochem Biophys Res Commun 1996; 225: 1021-6.
29. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci 1977; 74: 5463-7.
30. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
31. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA; 1984; 81: 1991-5.
32. Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL. DNA flow cytometry and prognostic factors in 1131 frozen breast cancer specimens. Cancer 1988; 61: 420-7.
33. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973; 51: 1409-16.
34. Partridge CR, Hawker JR, Forough R. Overexpression of a secretory form of FGF-1 promotes MMP-1-mediated endothelial cell migration. J Cell Biochem 2000; 78: 487-99.
35. Rieck P, Peters D, Hartmann C, Courtois Y. A new rapid colorimetric assay for quantitative determination of cellular proliferation, growth inhibition, and viability. J Tiss Cult Meth 1993; 15: 37-42.
36. Prudovsky I, Savion N, Zhan X, et al. Intact and functional fibroblast growth factor (FGF) receptor-1 trafficks near the nucleus in response to FGF-1. J Biol Chem 1994; 269: 31720-4.
37. Chevallier B, Heintzmann F, Mosseri V, et al. Prognostic value of estrogen and progesterone receptors in operable breast cancer. Cancer 1988; 62: 2517-24.
38. Thorpe SM, Rose C, Rasmussen BB, Mouridsen HT, Bayer T, Keiding N. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 1987; 47: 6126-33.
39. Luttrell DK, Lee A, Lansing TJ, et al. Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc Natl Acad Sci USA 1994; 91: 83-7.
40. Ottenholf-Kalff AE, Rijksen G, van Beurden EACM, Hennipman A, Michels AA, Staal GEJ. Characterization of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product. Cancer Res 1992; 52: 4773-8.
41. Kurokawa H, Lenferink AE, Simpson JF, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000; 60: 5887-94.
42. Pegram MD, Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 1999; 26 (4 Suppl 12): 89-95.
43. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Clin Oncol 1996; 14: 737-44.
44. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999; 26 (4 Suppl 12): 78-83.